Century Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Century Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-20.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 57% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$117Sales grew 2,000% in 3 years; of every extra $100 of sales, $117 became extra profit.
Higher than 83% of Healthcare companies in United States.
Asset Productivity Ratio
+2000% / -54%In 3 years sales changed by +2000% while total assets changed by -54%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-31.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 64% of Healthcare companies in United States.
Cash Cushion Ratio
+26%Cash, after subtracting all debt, equals 26% of its market value (net cash).
Higher than 66% of Healthcare companies in United States.
Tangible Assets Ratio
85%Of every $100 the company owns, $85 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 55% of Healthcare companies in United States.
Tangible Net Worth Ratio
78%Of every $100 of net worth, $78 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 61% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Century Therapeutics, Inc. made a loss over the last year. Century Therapeutics, Inc. owes $0.19 for every $1 it owns. Century Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCentury Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.23The share price is 1.23 times Century Therapeutics, Inc.'s book value per share, lower than 74% of Healthcare companies in United States.
Market cap
$286 MThe total market value of all of Century Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 53% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$232 MWhat Century Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.28Net worth divided by the number of shares. The share price of $1.58 is 1.2 times this, which is the P/B above.
Return on equity (ROE)
-49.6%Century Therapeutics, Inc. lost 49.6% of its shareholders' money over the last year, lower than 51% of Healthcare companies in United States.
Owes vs Owns
0.19×Century Therapeutics, Inc. owes $0.19 for every $1 it owns (low), lower than 74% of Healthcare companies in United States.
Dividend yield
NoneCentury Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+1557%Revenue rose 1557% in the year to Dec 2025, and grew 176% a year on average over 3 years.
Profit growth
LossCentury Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-8.8%Century Therapeutics, Inc. lost $9 for every $100 of revenue.
Cash vs debt
Net cashCentury Therapeutics, Inc. held $74 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Century Therapeutics, Inc.: $286 M ÷ $232 M (30 Jun 2026) = 1.2.
What is Century Therapeutics, Inc.'s return on equity?
Century Therapeutics, Inc. lost 49.6% of its shareholders' money over the last year, lower than 51% of Healthcare companies in United States.
How much does Century Therapeutics, Inc. owe compared with what it owns?
Century Therapeutics, Inc. owes $0.19 for every $1 it owns (low), lower than 74% of Healthcare companies in United States.
Does Century Therapeutics, Inc. pay a dividend?
No. Century Therapeutics, Inc. does not currently pay a dividend.
Is Century Therapeutics, Inc.'s revenue growing?
Revenue rose 1557% in the year to Dec 2025, and grew 176% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.